The PEARL-C1 trial is a phase II open-label trial. Participants will receive a single high-dose (25 mg) of psilocybin in the context of Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy....
NCT ID: NCT07048743 Phase: PHASE2 Enrollment Target: 15 Status: Recruiting
The PEARL-C1 trial is a phase II open-label trial. Participants will receive a single high-dose (25 mg) of psilocybin in the context of Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy.
[Draft — editorial context needed]
Dave Asprey's annual biohacking conference featuring cutting-edge health optimization, longevity science, and performance technology demonstrations.
A major biohacking expo focused on wellness, longevity, and biohacking technologies, bringing together practitioners and innovators.
Stay Regulated
New research, honest product reviews, neurotech funding rounds, and events — delivered weekly, with zero sponsors or ads.